Perlara in the news

Recent Articles

Advocacy Groups as Investors

Perlara signs pact with Grace Science and Wylder Nation Foundation

Young scientists ditch postdocs for biotech start-ups

Perlara signs rare disease pact with Novartis

YC-backed Perlstein Lab continues rare disease drug discovery

The Indie Scientist who vows to Leave no Mutation Behind

Nematodes and Your Compounds

Career Profiles–Into the wild

Lacking Funding, Some Scientists Turn to the Crowd

With $2M Seed, Perlstein Lab Tests Unorthodox Rare-Disease Plan

How a biotech startup juiced investors with yeast, flies and zebra fish

Perlstein Lab Raises $2 Million for Orphan Drug Discovery

Scientist’s Experiment in Fundraising

A Year Late: Indie Scientist, Ethan Perlstein

Scenes from the Postdocalypse

Press Releases

January 31, 2017
Perlara Announces Third Patient Advocacy Group Partnership

January 10, 2017
Perlara PBC Announces Patient Advocacy Group Partnerships

October 19, 2016
Perla ra PBC Announces Pharma Collaboration

July 31, 2014
Perlstein Lab Seed Round

The latest from our blog

World Rare Disease Day 2017

by Ethan Perlstein | Mar 8, 2017 | Perlara science | 0 Comments

This post is dedicated to World Rare Disease Day (WRDD) 2017. It was at the WRRD four years earlier when the value proposition for Perlara crystalized in my mind. I went to NIH that frosty last day of February in order to meet with patient advocates and ask them one...

Optimizing my first High Throughput Screen

by Feba Sam | Feb 1, 2017 | Perlara science | 1 Comment

I, along with Nina, performed our first high-throughput screen – well really medium-throughput but high-throughput for us – on Niemann-Pick Type C (NPC) patient-derived fibroblasts a couple of months back. We wanted to do a pilot screen with the Microsource bioactives...

NPC1 KO mouse brain study

by Nina DiPrimio | Jan 12, 2017 | Perlara science | 0 Comments

Well it has been a little while since I wrote a post, and a lot has happened since then, which I am sure you read about in our blogs and tweets. We changed our company name, partnered with Novartis and started partnering with patient groups to engineer our organisms...